1. Asenapine effects in animal models of psychosis and cognitive function
- Author
-
Marston, Hugh M., Young, Jared W., Martin, Frederic D., Serpa, Kevin A., Moore, Christopher L., Wong, Erik H., Gold, Lisa, Meltzer, Leonard T., Azar, Marc R., Geyer, Mark A., and Shahid, Mohammed
- Subjects
Biomedicine ,Psychiatry ,Pharmacology/Toxicology ,Neurosciences ,Five-choice serial reaction ,Attention ,Amphetamine ,Apomorphine ,Antipsychotic ,Asenapine ,Delayed non-match to place ,Locomotor activity ,Prepulse inhibition ,Short-term spatial memory - Abstract
Asenapine, a novel psychopharmacologic agent in the development for schizophrenia and bipolar disorder, has high affinity for serotonergic, α-adrenergic, and dopaminergic receptors, suggesting potential for antipsychotic and cognitive-enhancing properties.The effects of asenapine in rat models of antipsychotic efficacy and cognition were examined and compared with those of olanzapine and risperidone.Amphetamine-stimulated locomotor activity (Amp-LMA; 1.0 or 3.0 mg/kg s.c.) and apomorphine-disrupted prepulse inhibition (Apo-PPI; 0.5 mg/kg s.c.) were used as tests for antipsychotic activity. Delayed non-match to place (DNMTP) and five-choice serial reaction (5-CSR) tasks were used to assess short-term spatial memory and attention, respectively. Asenapine doses varied across tasks: Amp-LMA (0.01–0.3 mg/kg s.c.), Apo-PPI (0.001–0.3 mg/kg s.c.), DNMTP (0.01–0.1 mg/kg s.c.), and 5-CSR (0.003–0.3 mg/kg s.c.).Asenapine was highly potent (active at 0.03 mg/kg) in the Amp-LMA and Apo-PPI assays. DNMTP or 5-CSR performance was not improved by asenapine, olanzapine, or risperidone. All agents (P
- Published
- 2009